{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:44:38Z","timestamp":1790181878127,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aspenjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nut in Clin Prac"],"published-print":{"date-parts":[[2024,6]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Chronic hepatic complications are common in patients with short bowel syndrome\u2013associated intestinal failure (SBS\u2010IF). Teduglutide, a glucagon\u2010like peptide\u20102 analogue, demonstrated efficacy in reducing parenteral nutrition and\/or intravenous fluid dependence among patients with SBS\u2010IF in phase 3 clinical studies.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This was a post hoc analysis of pooled data from two separate randomized, double\u2010blind, placebo\u2010controlled, multinational phase 3 clinical studies. Adult patients with SBS\u2010IF with parenteral nutrition and\/or intravenous fluid dependence without liver disease at baseline were randomized to treatment with the glucagon\u2010like peptide\u20102 analogue teduglutide (0.05 or 0.10\u2009mg\/kg\/day) or placebo subcutaneously once daily for 24 weeks. Mixed\u2010effects models assessed the baseline predictors of change in liver chemistries.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between baseline and week 24, teduglutide treatment (\n n<\/jats:italic>\n \u2009=\u2009109) was associated with least squares mean reductions in aspartate aminotransferase (\u20137.51 IU\/L;\n P<\/jats:italic>\n \u2009=\u20090.014), alanine aminotransferase (\u201312.15\u2009IU\/L;\n P<\/jats:italic>\n \u2009=\u20090.002), and bilirubin (\u20135.03\u2009\u00b5mol\/L [\u20130.057\u2009mg\/dl];\n P<\/jats:italic>\n \u2009<\u20090.001) compared with that of the placebo (\n n<\/jats:italic>\n \u2009=\u200959). These values were independent of reductions in parenteral nutrition and\/or intravenous fluid dependence.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Teduglutide treatment was associated with reductions in liver chemistries by week 24, which is beneficial for patients with SBS\u2010IF beyond improvements in parenteral nutrition and\/or intravenous fluid dependence. Future studies should examine how long\u2010term teduglutide might mitigate the risk of liver disease in patients with SBS\u2010IF.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/ncp.11139","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T10:57:46Z","timestamp":1710586666000},"page":"634-640","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Teduglutide improves liver chemistries in short bowel syndrome\u2013associated intestinal failure: Post hoc analysis"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-1670","authenticated-orcid":false,"given":"Dejan","family":"Micic","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Robinson","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Kidd","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Terreri","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram P.","family":"Raphael","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2019.11.013"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.10.002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/968357"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.10.066"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000594"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0797-673"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021113-170317"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2000.278.1.E134"},{"key":"e_1_2_10_12_1","unstructured":"Takeda. Gattex prescribing information. Accessed May 26 2023.https:\/\/www.shirecontent.com\/PI\/PDFS\/Gattex_USA_ENG.pdf"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.09.007"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.69"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10092"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.10.027"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1690"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.218271"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.023"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.05.004"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.004"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2224"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15017"}],"container-title":["Nutrition in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ncp.11139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:35:03Z","timestamp":1760967303000},"score":1,"resource":{"primary":{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/10.1002\/ncp.11139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/ncp.11139"],"URL":"https:\/\/doi.org\/10.1002\/ncp.11139","archive":["Portico"],"relation":{},"ISSN":["0884-5336","1941-2452"],"issn-type":[{"value":"0884-5336","type":"print"},{"value":"1941-2452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"2023-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}